

February 13, 2020



Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board

Leading research expert in developing new therapeutic tools to treat hematologic malignancies and solid tumors using adoptive cell therapy

Dr. Mamonkin is a faculty member in the Center for Cell and Gene Therapy at Baylor College of Medicine

FRAMINGHAM, MA / ACCESSWIRE / February 13, 2020 / [Xenetic Biosciences, Inc.](#)

(NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today it has strengthened its Scientific Advisory Board ("SAB") with the appointment of Maksim Mamonkin, Ph.D., to aid in the development of the Company's XCART™ program for the treatment of B-cell lymphomas.

"We are thrilled to have attracted Dr. Mamonkin, a leading expert in advanced CAR T research, and welcome him to our Scientific Advisory Board. His work in the development of new therapeutic tools to treat hematologic malignancies and solid tumors using adoptive cell therapy will provide key insight as we look to advance XCART™," commented [Jeffrey Eisenberg, Chief Executive Officer](#) of Xenetic.

Dr. Mamonkin currently serves as an Assistant Professor in the Center for Cell and Gene Therapy and maintains academic appointment in the Department of Pathology and Immunology at Baylor College of Medicine in Houston, Texas. Dr. Mamonkin directs a laboratory that focuses on investigating the mechanisms and effects of CAR signaling in therapeutic T cells and developing new engineered approaches using genome editing and synthetic biology to enhance cell therapy of aggressive hematologic malignancies. He oversees clinical translation of investigational therapies through cGMP manufacturing to the clinic and serves as a co-principal investigator on several ongoing and upcoming clinical trials of CAR T cells in hematologic malignancies at Baylor College of Medicine.

"My team and I have developed a number of CAR T-cell products for aggressive leukemia and lymphoma, and the approach being developed at Xenetic looks very intriguing to me. The pre-clinical data demonstrated to date by the XCART™ platform shows potential noteworthy benefits over the existing and currently approved CAR T therapies. I look forward to working alongside the Xenetic team and leveraging my experience to further advance the development of the XCART™ platform," commented Dr. Mamonkin.

Dr. Mamonkin received his Ph.D. in Immunology at Baylor College of Medicine studying the transcriptional regulation of T-cell differentiation in response to bacterial infection and completed his postdoctoral training with Dr. Malcolm Brenner at the Center for Cell and Gene Therapy, Baylor College of Medicine.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at www.xeneticbio.com and connect on [Twitter](#), [LinkedIn](#), and [Facebook](#).

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding the Company's plans to initially apply the XCART technology to advance cell-based therapeutics by targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas, and the Company's expectations that XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the acquisition of the CAR T technology; (2) uncertainty of the expected financial performance of the Company following completion of the acquisition of the CAR T technology; (3) failure to realize the anticipated potential of the XCART technology; (4) the ability of the Company to implement its business strategy; and (5) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors,

competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/576179/Xenetic-Biosciences-Inc-Strengthens-Expertise-to-Advance-XCART-Development-Program-with-Appointment-of-Cell-Therapy-Expert-Maksim-Mamonkin-PhD-to-Scientific-Advisory-Board>